Status:
COMPLETED
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
Lead Sponsor:
Pulmagen Therapeutics
Conditions:
Atopic Asthma
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This study is to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B administered once daily for 28 days in subjects with partly controlled atopic asthma.
Eligibility Criteria
Inclusion
- Partially controlled mild-moderate atopic asthma
- Receiving inhaled corticosteroids
- Non-smoker or former smoker
- Males and females aged 18 to 55 years inclusive
- If female, must be of non-childbearing potential
Exclusion
- History of acute severe asthma attacks
- History of COPD
- Other serious respiratory or other medical condition which may interfere with the outcome of the study
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2012
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01448954
Start Date
September 1 2011
End Date
February 1 2012
Last Update
February 20 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Belfast, United Kingdom, BT9 6AD
2
Manchester, United Kingdom, M23 9QZ